Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • P2Y11 Antagonist B7508: Novel Insights into GPCR and Canc...

    2026-01-15

    P2Y11 Antagonist B7508: Novel Insights into GPCR and Cancer Invasion

    Introduction: Unraveling the Complexities of P2Y11 Antagonism

    The P2Y11 receptor, a member of the P2Y family of G protein-coupled receptors (GPCRs), has emerged as a pivotal modulator in cell signaling, inflammation, and oncogenic processes. While several resources explore the mechanisms and workflows for employing P2Y11 antagonists in immunology and neuroinflammation research (see this mechanistic overview), there remains a critical need for deeper contextualization of the antagonist’s role in the nexus between purinergic signaling and cancer invasiveness. This article addresses that gap, providing a comprehensive analysis of the APExBIO P2Y11 antagonist (SKU: B7508), its scientific underpinnings, and its unique potential in translational research.

    Product Profile: Chemical and Biophysical Properties

    The P2Y11 antagonist (SKU: B7508) is chemically defined as sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate (C37H26N4Na4O15S4), with a molecular weight of 986.84. Supplied as a beige solid, it is highly water-soluble (<19.74 mg/ml), and is stable when stored at -20°C. To ensure product integrity, shipping is performed on blue ice, and users are advised to avoid long-term solution storage due to potential degradation. As a research-exclusive reagent, it is not intended for diagnostic or clinical use.

    Mechanism of Action: P2Y11 Antagonist as a Targeted Cell Signaling Inhibitor

    The P2Y11 receptor is unique within the P2Y family, being dually coupled to Gq and Gs proteins, enabling it to regulate multiple downstream effectors including adenylate cyclase and phospholipase C. The B7508 P2Y11 antagonist functions as a cell signaling inhibitor targeting the P2Y11 receptor, disrupting both cyclic AMP (cAMP) and inositol triphosphate (IP3) mediated signaling cascades. This antagonism provides precise control over GPCR signaling pathways, making B7508 a robust tool for dissecting purinergic signaling in cellular models.

    Antagonizing the P2Y11 Receptor in Disease Contexts

    Beyond classical immunology applications, recent research highlights the P2Y11 receptor’s involvement in cancer cell migration and invasion, particularly in breast cancer. The reference study by Liu et al. (Front. Endocrinol. 2021) demonstrated that P2Y11 antagonism via NF340 (the compound underlying B7508) reversed the pro-invasive signaling induced by upregulated quinolinate phosphoribosyltransferase (QPRT). This effect is mechanistically linked to decreased phosphorylation of myosin light chain, an essential regulator of cytoskeletal dynamics and metastatic potential. Such findings extend the utility of P2Y11 antagonists well beyond their established roles in inflammation pathway modulation and immunology research.

    Comparative Analysis: Unveiling New Directions Beyond Standard Workflows

    Existing literature, such as the workflow-centric guide on applied workflows for GPCR signaling, primarily focuses on experimental processes and troubleshooting. In contrast, this article centers on emerging mechanistic insights and the translational potential of P2Y11 antagonism in complex disease models. By connecting purinergic signaling with metabolic reprogramming and cytoskeletal regulation, we illuminate novel research avenues not fully explored in prior content.

    • Existing resources detail the specificity and reproducibility of B7508 in standard cell signaling and inflammation assays.
    • This article uniquely contextualizes the antagonist’s role in modulating the interplay between NAD+ metabolism, GPCR signaling, and cancer cell invasiveness, with direct reference to primary literature.

    Furthermore, while other articles emphasize the precision of B7508 for GPCR pathway interrogation, our analysis delves into how its antagonism disrupts metastatic signaling networks, thus opening new possibilities for autoimmune disease research and neuroinflammation studies with direct clinical relevance.

    Advanced Applications: P2Y11 Antagonist in Translational Oncology and Immunology

    Leveraging B7508 for Cancer Invasion Research

    The ability of B7508 to block P2Y11 receptor activity has profound implications for oncology. As shown in Liu et al. (2021), P2Y11 antagonism counteracts QPRT-induced invasiveness in breast cancer cells. This effect traces to the modulation of myosin light chain phosphorylation—an essential determinant of tumor cell motility. The capacity to dissect this signaling axis positions B7508 as an indispensable tool for studying metastatic mechanisms and identifying potential therapeutic targets in aggressive cancers.

    Unlike prior articles that focus on general GPCR pathway modulation, we emphasize how the integration of P2Y11 antagonism with metabolic pathway inhibitors (e.g., targeting NAD+ biosynthesis) enables multi-layered interrogation of cancer cell biology. This dual inhibition strategy can reveal compensatory mechanisms and uncover vulnerabilities exploitable in drug development pipelines.

    Applications in Autoimmune and Neuroinflammatory Models

    The role of P2Y11 signaling in the immune system extends to regulating cytokine release, leukocyte migration, and tissue inflammation. As a highly selective G protein-coupled receptor antagonist, B7508 facilitates studies of inflammatory pathway modulation at both the cellular and systemic level. Recent advances suggest its utility in dissecting the molecular basis of autoimmune diseases, where dysregulated GPCR signaling contributes to pathogenesis. In neuroinflammation studies, B7508 can be leveraged to parse the contribution of P2Y receptor signaling to neuroimmune cross-talk and blood-brain barrier integrity.

    This translational approach builds upon—but goes beyond—the advanced mechanistic focus of resources like "Unraveling GPCR Signaling and Breast Cancer Invasiveness", by explicitly connecting P2Y11 antagonism to metabolic and cytoskeletal pathways in the context of clinical research needs.

    Experimental Best Practices and Considerations

    For optimal results, B7508 solutions should be freshly prepared and used promptly to maintain activity. Its robust solubility (<19.74 mg/ml in water) allows for a range of dosing regimens. Researchers should store the solid compound at -20°C and avoid repeated freeze-thaw cycles. In experiments where long-term solution stability is a concern, aliquoting and minimizing exposure to ambient conditions are recommended.

    Researchers utilizing APExBIO's P2Y11 antagonist should also consider integrating it with orthogonal inhibitors (e.g., Rho, ROCK, PLC, MLCK) as demonstrated in the Liu et al. study, to interrogate network-level effects on cell signaling and migration. The combined use of these agents can distinguish direct purinergic effects from broader GPCR pathway alterations.

    Future Outlook: Expanding the Frontier of GPCR and Cancer Research

    The intersection of purinergic and metabolic signaling, as highlighted by the P2Y11 antagonist, opens new investigative paths in cancer biology, immunology, and beyond. Critical future directions include:

    • Elucidating the role of P2Y11 antagonism in other cancer types with aberrant NAD+ metabolism.
    • Developing combinatorial strategies that target both GPCR and metabolic pathways to thwart tumor progression.
    • Expanding applications in chronic inflammatory and neurodegenerative disease models to identify novel therapeutic avenues.

    For researchers seeking a comprehensive, scientifically validated solution for probing GPCR signaling, the P2Y11 antagonist (B7508) stands out as a versatile and powerful tool. By integrating mechanistic depth, translational relevance, and methodological rigor, this article provides a differentiated perspective—bridging the gap between standard workflows, as detailed in practical scenario-based guides, and advanced, hypothesis-driven research.

    Conclusion

    The APExBIO P2Y11 antagonist B7508 is more than a conventional cell signaling inhibitor. Its ability to modulate GPCR and downstream cytoskeletal signaling, particularly in the context of cancer invasiveness and autoimmune disease research, positions it at the forefront of modern biochemical investigation. By building upon, contrasting with, and extending beyond existing literature, this article underscores the compound’s unique contributions to advancing both fundamental and translational science. For in-depth support of your research, explore the P2Y11 antagonist today.